Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029592

Enrollment

Unknown

Registered

2020-02-05

Start date

2020-02-07

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Two cohorts:Arbidol cohort versus without Arbidol cohort

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: High-risk population including medical staff on duty during the outbreak of 2019-nCoV pneumonia.

Exclusion criteria

Exclusion criteria: 1. People with high-risk exposure who are unwilling to participate in this survey; 2. People with high-risk exposure who want to withdraw from the research during the study.

Design outcomes

Primary

Measure	Time frame
2019-nCoV RNA;2019-nCoV antibody;Chest CT;	—

Countries

China

Contacts

Public ContactXin Zheng

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

xin11@hotmail.com+86 027 85726732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026